William Blair Forecasts uniQure’s Q1 Earnings (NASDAQ:QURE)

uniQure (NASDAQ:QURE) – Equities researchers at William Blair cut their Q1 2025 earnings estimates for uniQure in a report released on Thursday, February 27th. William Blair analyst S. Corwin now expects that the biotechnology company will post earnings per share of ($1.48) for the quarter, down from their previous forecast of ($0.73). The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. William Blair also issued estimates for uniQure’s Q2 2025 earnings at ($1.48) EPS, Q3 2025 earnings at ($1.37) EPS, Q4 2025 earnings at ($1.37) EPS, FY2025 earnings at ($5.69) EPS and FY2026 earnings at ($5.28) EPS.

Several other research firms also recently commented on QURE. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Wednesday, February 5th. Wells Fargo & Company lowered their price objective on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. Mizuho lifted their price objective on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. Cantor Fitzgerald lifted their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 10th. Finally, The Goldman Sachs Group lifted their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and an average target price of $38.89.

uniQure Price Performance

Shares of QURE opened at $11.33 on Monday. The company has a market cap of $552.26 million, a price-to-earnings ratio of -2.28 and a beta of 0.38. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a 50 day moving average of $14.80 and a two-hundred day moving average of $9.89.

Insider Buying and Selling

In other uniQure news, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the transaction, the chief financial officer now owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. The trade was a 1.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,915 shares of company stock valued at $588,112 over the last 90 days. Insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Twin Tree Management LP purchased a new stake in shares of uniQure during the fourth quarter worth about $77,000. FNY Investment Advisers LLC purchased a new stake in shares of uniQure during the fourth quarter worth about $88,000. RTW Investments LP purchased a new stake in shares of uniQure during the third quarter worth about $49,000. ADAR1 Capital Management LLC purchased a new stake in shares of uniQure during the fourth quarter worth about $177,000. Finally, Atria Investments Inc purchased a new stake in shares of uniQure during the third quarter worth about $53,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.